(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 June 2010 (03.06.2010)

PCT

(10) International Publication Number
WO 2010/061329 A1

(51) International Patent Classification:
C07D 487/08 (2006.01) *A61P 29/02* (2006.01)
A61K 31/407 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/IB2009/055232

(22) International Filing Date:
20 November 2009 (20.11.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/118,053 26 November 2008 (26.11.2008) US

(71) Applicant *(for all designated States except US)*: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DEVRAJ, Rajesh Venkateswaran** [IN/US]; Pfizer Global Research & Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017 (US). **HUANG, Wei** [US/US]; Pfizer Global Research & Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017 (US). **HUGHES, Robert Owen** [GB/US]; Pfizer Global Research & Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017 (US). **ROGIER JR., Donald Joseph** [US/US]; Pfizer Global Research & Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017 (US). **TRUJILLO, John Isidro** [US/US]; Pfizer Global Research & Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017 (US). **TURNER, Steve Ronald** [US/US]; Pfizer Global Research & Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017 (US).

(74) Agents: **BENSON, Gregg C.** et al.; Pfizer Inc. Eastern Point Road, MS 9114, Groton, Connecticut 06340 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*


— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:


— *with international search report (Art. 21(3))*

WO 2010/061329 A1

(54) **Title**: 3-AMINOCYCLOPENTANECARBOXAMIDES AS CHEMOKINE RECEPTOR MODULATORS



I(a)



I(b)

(57) **Abstract**: There is provided a compound of Formula I(a) or I(b) or a pharmaceutically acceptable salt thereof, wherein the various substitutents are defined herein.